Jones Financial Companies
MGX icon

Jones Financial Companies’s Metagenomi Therapeutics MGX Stock Holding History

Jones Financial Companies’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$660 Hold
500
– – ﹤0.01% 4449
2025
Q4 		$810 Hold
500
– – ﹤0.01% 4067
2025
Q3 		$1.15K Hold
500
– – ﹤0.01% 3858
2025
Q2 		$730 Hold
500
– – ﹤0.01% 3727
2025
Q1 		$740 Buy
+500
New +$1.19K ﹤0.01% 3463

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jones Financial Companies's MGX Position: Q1 2026 in Review

Jones Financial Companies held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 500 shares worth $660. The position accounts for ﹤0.01% of the portfolio, ranked #4449.

Jones Financial Companies first reported a position in MGX in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.15K in Q3 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Jones Financial Companies held 500 shares of Metagenomi Therapeutics worth $660 as of Q1 2026.
  • Jones Financial Companies left its Metagenomi Therapeutics share count unchanged in Q1 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4449 holding.
  • Jones Financial Companies first reported a position in Metagenomi Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Jones Financial Companies's Metagenomi Therapeutics position peaked at $1.15K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.